alendronate has been researched along with Hypergonadotropic Hypogonadism in 5 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Denosumab and alendronate showed similar clinical efficacy in the therapy of ADT-related osteoporosis in men with prostate carcinoma; both drugs provided significant improvements in back pain and general health conditions." | 9.24 | Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate. ( Balsano, M; Doria, C; Maestretti, G; Mosele, GR; Scarpa, RM; Solla, F, 2017) |
| " Our results support the long-term administration of alendronate along with testosterone replacement to men with hypogonadism-induced osteoporosis." | 6.71 | Alendronate for osteoporosis in men with androgen-repleted hypogonadism. ( Doolman, R; Eshed, V; Karasik, A; Sela, BA; Shimon, I; Vered, I, 2005) |
| "Denosumab and alendronate showed similar clinical efficacy in the therapy of ADT-related osteoporosis in men with prostate carcinoma; both drugs provided significant improvements in back pain and general health conditions." | 5.24 | Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate. ( Balsano, M; Doria, C; Maestretti, G; Mosele, GR; Scarpa, RM; Solla, F, 2017) |
| " Our results support the long-term administration of alendronate along with testosterone replacement to men with hypogonadism-induced osteoporosis." | 2.71 | Alendronate for osteoporosis in men with androgen-repleted hypogonadism. ( Doolman, R; Eshed, V; Karasik, A; Sela, BA; Shimon, I; Vered, I, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doria, C | 1 |
| Mosele, GR | 1 |
| Solla, F | 1 |
| Maestretti, G | 1 |
| Balsano, M | 1 |
| Scarpa, RM | 1 |
| Morgan Ortiz, F | 1 |
| Meza Mendoza, C | 1 |
| Beltrán Lugo, I | 1 |
| Caballero RodrÃguez, B | 1 |
| Contreras Soto, JO | 1 |
| Ringe, JD | 1 |
| Shimon, I | 1 |
| Eshed, V | 1 |
| Doolman, R | 1 |
| Sela, BA | 1 |
| Karasik, A | 1 |
| Vered, I | 1 |
| Tanimoto, K | 1 |
| Okubo, Y | 1 |
| Harada, C | 1 |
| Saito, H | 1 |
| Sata, A | 1 |
| Nishikawa, A | 1 |
| Ohwada, R | 1 |
| Tsuiki, M | 1 |
| Yamamoto, M | 1 |
| Hashimoto, E | 1 |
| Sato, K | 1 |
| Takano, K | 1 |
1 review available for alendronate and Hypergonadotropic Hypogonadism
| Article | Year |
|---|---|
[Osteoporosis in men].
Topics: Alendronate; Androgens; Calcium Channel Blockers; Diagnosis, Differential; Etidronic Acid; Fractures | 2003 |
2 trials available for alendronate and Hypergonadotropic Hypogonadism
| Article | Year |
|---|---|
Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Denosumab; Double-Blind Meth | 2017 |
Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Topics: Adult; Aged; Alendronate; Amino Acids; Androgens; Biomarkers; Bone Density; Bone Density Conservatio | 2005 |
2 other studies available for alendronate and Hypergonadotropic Hypogonadism
| Article | Year |
|---|---|
[Resistant ovary syndrome. Case report].
Topics: Adolescent; Alendronate; Bone Density Conservation Agents; Estrogens; Female; Hormone Replacement Th | 2011 |
Latent hypoparathyroidism in an osteoporotic patient with multiple endocrinopathies and secondary hemochromatosis due to multiple blood transfusions, unmasked by alendronate and glucocorticoid at adrenal crisis.
Topics: Adrenal Glands; Adult; Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcium; Diab | 2008 |